There are currently no FDA-approved therapies to treat this condition. QTORIN™ rapamycin is a topical gel designed to target the underlying drivers of cutaneous VMs by inhibiting the mTOR pathway.

In December 2023, Palvella partnered with Ligand Pharmaceuticals for the Phase III trial of topical Qtorin rapamycin to treat ...

In a 2019 randomized clinical study with topical rapamycin, an improvement in skin appearance, including a reduction in wrinkles, was accompanied by a significant increase (P < .008) in collagen ...

Charles Sawyers and colleagues have conducted a small early-stage clinical study to assess target modulation by the small-molecule inhibitor rapamycin. Rapamycin is approved to treat renal cancer ...